Merck's KEYTRUDA plus concurrent chemoradiotherapy has shown significant improvement in progression-free survival in newly diagnosed, high-risk locally advanced cervical cancer patients. The treatment reduced the risk of disease progression or death by 30% compared to concurrent chemoradiotherapy alone. This is the first Phase 3 study where an immunotherapy regimen has demonstrated a significant PFS improvement in locally advanced cervical cancer.